Clinical trials: Hepatitis C Virus (HCV)
Hepatitis C
Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection
This study is to evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in adults with nosocomial genotype 1 hepatitis C virus (HCV) infection.
- Trial name
- NCT01924949
- Testing
- LDV/SOF
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Gilead Sciences
Hepatitis C
Effects of Direct Antiviral Agents on Hepatitis C Virus Arthropathy
The prevalence of HCV infection in Egypt is 14.7%. HCV is both a hepatotropic and a lymphotropic virus, it may exert a chronic stimulus on the immune system with both T and B lymphocyte alterations.
- Trial name
- NCT03226717
- Testing
- Antiviral agents
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Hepatitis C
Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV
A single-arm, multi-center study of HCV-1b patients without baseline non-structure protein (NS5A) resistance-associated variants.
- Trial name
- NCT03004625
- Testing
- daclatasvir, asunaprevir, Ribavirin
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Liver Fibrosis
Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection
Patients who have been treated for hepatitis C virus (HCV) infection who have failed to respond to anti-viral treatment are often concerned about their ongoing liver disease and are therefore looking for alternative treatments…
- Trial name
- NCT00180674
- Testing
- Warfarin
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- Imperial College London
Chronic Hepatitis C Infection
Triple Combination DAAs for Treating HCV GT1b Subjects
There is only one kind of treatment (simeprevir 150 mg + sofosbuvir 400 mg+daclatasvir 60 mg) in this study but the treatment duration may be different depending on patients' response to the antiviral therapy and whether patients…
- Trial name
- NCT02932293
- Testing
- SOF+DCV+SMV
- Where
- Hong Kong
- Sponsor
- Humanity and Health Research Centre
Hepatitis C, Chronic
GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection
The purpose of this phase 2 study is to determine whether 30 mg or 90 mg of GS-5885 when given with GS-9451, Tegobuvir and Ribavirin (RBV) for 12 or 24 weeks is effective, safe and tolerable in the treatment of Chronic Genotype 1…
- Trial name
- NCT01353248
- Testing
- GS-5885, Tegobuvir, GS-9451
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 141 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols
This single arm study will provide treatment or re-treatment with PEGASYS as monotherapy or in combination with ribavirin (Copegus), to patients with chronic hepatitis C (CHC) who have participated in a previous Roche or Roche…
- Trial name
- NCT00800735
- Testing
- Pegylated-interferon alfa-2a, Ribavirin
- Where
- 23 sites in United States, Austria and 4 more
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients
This 7 cohort study will evaluate the efficacy and safety of combination treatment with an HCV nucleoside polymerase inhibitor(RO5024048)and an HCV protease inhibitor(RO5190591/ITMN-191/danoprevir) in patients with chronic…
- Trial name
- NCT00801255
- Testing
- RO5024048, danoprevir
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 88 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
Impact of the Sustained Viral Response of Chronic Hepatitis c After Treatment With Direct Action Antivirals
The purpose of this study is to evaluate the evolution of liver injury with fibrosis data obtained using non-invasive serological markers in patients who achieved SVR after treatment with direct-acting antivirals.
- Trial name
- Hepatitis (NCT05062408)
- Where
- Spain
- Volunteers
- 321 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Chronic Hepatitis C Infection
Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
Objectives: 1) To evaluate la proportion of hepatitic C virus (HCV)-monoinfected patients who show sustained virologic response (SVR) to treatment including direct-acting antivirals (DAAs) in the clinical practice in clinical…
- Trial name
- FPSMON201401 (NCT02333292)
- Testing
- Telaprevir, Boceprevir, Sofosbuvir
- Where
- Spain
- Volunteers
- 1,128 people
- Sponsor
- Valme University Hospital
HBV/HCV Co-infection
NUC in Preventing HBV Reactivation in HCV/HBV Co-infected Patients Receiving DAA for CHC
HBV reactivation is common in HCV/HBV coinfected patients receiving DAA therapy for chronic hepatitis C. How to prevent HBV reactivation remains unclear.
- Trial name
- NCT04405011
- Testing
- 24-week Entecavir, 12-week Entecavir
- Where
- 2 sites in Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taiwan University Hospital
HEPATITIS C (HCV), Hepatitis B Virus (HBV)
Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France
In Mongolia, mortality from hepatocellular carcinoma (HCC) is one of the highest in the world. Viral hepatitis is the main cause of HCC: the prevalence of hepatitis B (HBV) estimated at 11% In Mongolia, hepatitis C (HCV) at 8.5%…
- Conditions
- HEPATITIS C (HCV), Hepatitis B Virus (HBV), Hepatitis D, Hepatocellular Carcinoma (HCC)
- Trial name
- Mondelta (NCT07038863)
- Testing
- Community screening for hepatitis B, C and delta in the Mongolian population living in France
- Where
- 11 sites in France
- Volunteers
- 2,000 people
- Sponsor
- Hospices Civils de Lyon
End Stage Renal Disease
A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients
The Transplanting Hepatitis C Kidneys into Negative KidnEy Recipients [THINKER-NEXT] study will include adult kidney transplant candidates without hepatitis C virus (HCV) infection on the transplant waiting list who will consent…
- Trial name
- THINKER-NEXT (NCT04075916)
- Testing
- Epclusa
- Where
- 11 sites in United States
- Volunteers
- 201 people
- Sponsor
- University of Pennsylvania
Hepatitis C
Screening for Hepatitis C Using a Rapid Diagnostic Orientation Test (TROD) in Patients Over 50 Years Old in the Digestive Endoscopy Department of the Europeen Hospital Marseille
Chronic viral hepatitis C is a public health problem and several management recommendations are available. According to the French High Authority of Health, hepatitis C screening consists of a targeted screening of people at risk…
- Trial name
- TROCENDO (NCT05103085)
- Testing
- Rapid diagnostic orientation test (TROD) for Hepatitis C
- Where
- France
- Volunteers
- 5,000 people
- Sponsor
- Hôpital Européen Marseille
Hepatitis C Virus Infection
Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection
This study will have two parts as follows: The PK Lead-in Phase of the study will evaluate the steady state pharmacokinetics (PK) and confirm the dose of sofosbuvir (SOF) in hepatitis C virus (HCV)-infected pediatric…
- Trial name
- NCT02175758
- Testing
- SOF, RBV
- Where
- 37 sites in United States, Australia and 6 more
- Volunteers
- 106 people
- Sponsor
- Gilead Sciences
Hepatitis C Virus Infection, Hepatitis C Virus Infection, Response to Therapy of
HCV Reinfection in in HIV/HCV-coinfected Patients Achieving SVR by Antiviral Therapy
Chronic hepatitis C virus (HCV) infection remains a health burden in people living with human immunodeficiency virus (HIV). Interferon (IFN)-based therapy is the treatment of choice for HCV infection for HIV coinfected patients…
- Conditions
- Hepatitis C Virus Infection, Hepatitis C Virus Infection, Response to Therapy of, Human Immunodeficiency Virus (HIV) Coinfection
- Trial name
- NCT04768517
- Where
- 7 sites in Taiwan
- Volunteers
- 300 people
- Sponsor
- National Taiwan University Hospital
Hepatitis C, Chronic
Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients
The purpose of this study was to investigate antiviral activity, safety and pharmacokinetics of 5 days of monotherapy with BI 207127 in HCV genotype 1 (GT1) infected patients.
- Trial name
- NCT02176525
- Testing
- BI 207127 NA
- Volunteers
- 75 people
- Sponsor
- Boehringer Ingelheim
Chronic Hepatitis C Infection
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
This was a Phase 2/3, open-label, multicenter study to evaluate the pharmacokinetics (PK), efficacy, and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/RTV) with or without dasabuvir (DSV) and with or without ribavirin…
- Trial name
- ZIRCON (NCT02486406)
- Testing
- Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 64 people
- Sponsor
- AbbVie
Hepatitis C
Hepatitis C-Video vs. Brochure Education Delivery
The purpose of this study is to determine the most effective way to give patients information regarding hepatitis C virus infection.
- Trial name
- NCT04204447
- Testing
- Hepatitis C Educational Brochure, Hepatitis C Educational Video
- Where
- 2 sites in United States
- Volunteers
- 176 people
- Sponsor
- State University of New York at Buffalo
Hepatitis C
A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment
The purpose of this study is to evaluate the efficacy of 4 different regimens of TMC435 in combination with peginterferon alfa-2a (PegIFNα-2a) and ribavirin (RBV), defined as the proportion of patients with sustained virologic…
- Trial name
- PILLAR (NCT00882908)
- Testing
- TMC435, Ribavirin (R), PegIFNα-2a (P)
- Where
- 71 sites in United States, Australia and 11 more
- Volunteers
- 386 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.